Rivers-Auty, JackTapia, Victor SWhite, Claire SDaniels, Michael JdDrinkall, SamuelKennedy, Paul TSpence, Harry GYu, ShiGreen, Jack PHoyle, ChristopherCook, JamesBradley, AmyMather, Alison EPeters, RuthTzeng, Te-ChenGordon, Margaret JBeattie, John HBrough, DavidLawrence, Catherine B2021-04-262021-04-262021-03-31Rivers-Auty, J, Tapia, V S, White, C S, Daniels, M J, Drinkall, S, Kennedy, P T, Spence, H G, Yu, S, Green, J P, Hoyle, C, Cook, J, Bradley, A, Mather, A E, Peters, R, Tzeng, T-C, Gordon, M J, Beattie, J H, Brough, D & Lawrence, C B 2021, 'Zinc status alters Alzheimer's disease progression through NLRP3-dependent inflammation', Journal of Neuroscience, vol. 41, no. 13, pp. 3025-3038. https://doi.org/10.1523/JNEUROSCI.1980-20.20200270-6474https://hdl.handle.net/2164/16322Data collection and sharing for this project were funded by ADNI National Institutes of Health Grant U01 AG024904 and ADNI Department of Defense Award W81XWH-12-2-0012. ADNI is supported by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Company, Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. A.E.M. is a Food Standards Agency Fellow and is supported by the Biotechnology and Biological Sciences Research Council Institute Strategic Program Microbes in the Food Chain BB/R012504/1 and its constituent projects BBS/E/F/000PR10348 (Theme 1, Epidemiology and Evolution of Pathogens in the Food Chain) and BBS/E/F/000PR10351 (Theme 3, Microbial Communities in the Food Chain). J.R.-A. was a Future Leader Fellow supported by the Biotechnology and Biological Sciences Research Council fellowship grant (Understanding how dietary zinc and inflammation impact healthy ageing in the brain; BB/P01061X/1). This work was also supported by Alzheimer Society Project Grant AS-PG-2013-007 to C.B.L. and D.B. that funded the salary of J.R.-A. The Histology Facility equipment that was used in this study was purchased by the University of Manchester Strategic Fund. We thank the University of Manchester Biological Services Facility and their expert animal husbandry, the Bioimaging Facility, and the Histology Facility for making this work possible.143874762engAPP/PS1Alzheimer's diseaseInflammationMicrogliaNLRP3ZincR MedicineGeneral NeuroscienceBiotechnology and Biological Sciences Research Council (BBSRC)BB/R012504/1BBS/E/F/000PR10348BBS/E/F/000PR10351BB/P01061X/1Alzheimers Research UKAS-PG-2013-007RJournal article10.1523/JNEUROSCI.1980-20.2020http://www.scopus.com/inward/record.url?scp=85103630529&partnerID=8YFLogxK4113